top of page
Diapin Pipeline: At the Forefront of Cardiovascular & Metabolic Disease Treatment Innovation
Product Candidates
DT678
The IND for DT678 has been filed in the US and China and Phase 1 SAD, MAD, Food Effect and Drug-drug interaction studies have been completed. Long term chronic toxicology studies have been completed for DT678 and a Phase 2 study is planned.
DT109
Non clinical pharmacology work for DT-109 has been completed (Publications). DT109 has shown efficacy for the treatment of MASH in mouse and nonhuman primates and also anti-atherosclerotic benefits. Nonclinical IND enabling studies are in progress.
bottom of page